BR112022011945A2 - Moléculas bifuncionais compreendendo uma variante de il-7 - Google Patents

Moléculas bifuncionais compreendendo uma variante de il-7

Info

Publication number
BR112022011945A2
BR112022011945A2 BR112022011945A BR112022011945A BR112022011945A2 BR 112022011945 A2 BR112022011945 A2 BR 112022011945A2 BR 112022011945 A BR112022011945 A BR 112022011945A BR 112022011945 A BR112022011945 A BR 112022011945A BR 112022011945 A2 BR112022011945 A2 BR 112022011945A2
Authority
BR
Brazil
Prior art keywords
variant
bifunctional molecules
bifunctional
molecules
variants
Prior art date
Application number
BR112022011945A
Other languages
English (en)
Inventor
Poirier Nicolas
Mary Caroline
Morello Aurore
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Priority claimed from PCT/EP2020/086600 external-priority patent/WO2021122866A1/en
Publication of BR112022011945A2 publication Critical patent/BR112022011945A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MOLÉCULAS BIFUNCIONAIS COMPREENDENDO UMA VARIANTE DE IL-7. A presente invenção se refere a variantes de IL-7, moléculas bifuncionais que a compreendem e seus usos.
BR112022011945A 2019-12-17 2020-12-17 Moléculas bifuncionais compreendendo uma variante de il-7 BR112022011945A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306671 2019-12-17
PCT/EP2020/086600 WO2021122866A1 (en) 2019-12-17 2020-12-17 Bifunctional molecules comprising an il-7 variant

Publications (1)

Publication Number Publication Date
BR112022011945A2 true BR112022011945A2 (pt) 2022-09-06

Family

ID=82482494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011945A BR112022011945A2 (pt) 2019-12-17 2020-12-17 Moléculas bifuncionais compreendendo uma variante de il-7

Country Status (11)

Country Link
US (1) US20230303648A1 (pt)
EP (1) EP4077364A1 (pt)
JP (1) JP2023506306A (pt)
KR (1) KR20220114637A (pt)
CN (1) CN114829385A (pt)
BR (1) BR112022011945A2 (pt)
CA (1) CA3159555A1 (pt)
CR (1) CR20220350A (pt)
IL (1) IL293745A (pt)
MX (1) MX2022007511A (pt)
PE (1) PE20221589A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162171A (zh) * 2022-10-13 2023-05-26 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用

Also Published As

Publication number Publication date
US20230303648A1 (en) 2023-09-28
KR20220114637A (ko) 2022-08-17
EP4077364A1 (en) 2022-10-26
CN114829385A (zh) 2022-07-29
JP2023506306A (ja) 2023-02-15
MX2022007511A (es) 2022-10-18
PE20221589A1 (es) 2022-10-10
CR20220350A (es) 2023-01-17
IL293745A (en) 2022-08-01
CA3159555A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
BR112021012037A2 (pt) Molécula anti-pd-1/il-7 bifuncional
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
BR112021012040A2 (pt) Molécula anti-pd-1/sirpa bifuncional
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
JP2020089354A5 (pt)
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
BR112019018036B8 (pt) Variante de aspartoquinase inovadora e método para produzir l-aminoácido com o uso da mesma
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
BR112016006048A8 (pt) composições antimicrobianas
BR112017028520A2 (pt) Sistemas adesivo de laminação - poliéster- policarbonato-poliol
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112022011945A2 (pt) Moléculas bifuncionais compreendendo uma variante de il-7
CL2020003414A1 (es) Tratamiento antidiabético cardiovascular seguro
CL2020002052A1 (es) Composiciones de edb que se dirigen a il-12.
BR112018076715A2 (pt) composição de alimento compreendendo uma protease ácida.
DOP2017000260A (es) Piroglutamato de vortioxetina
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
JP2019207083A5 (pt)
BR112019006830A2 (pt) pequenas moléculas ativadoras de ampk
BR112018077458A2 (pt) proteases aspárticas
JP2021062522A5 (pt)
NI201900006A (es) Combinaciã“n de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacã‰uticas de ã‰stos
JP2017176931A5 (pt)
BR112017007780A2 (pt) ?mancal deslizante feito de resina sintética?